Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00444132
• Date of registration: 06/03/2007
• Prospective Registration: No
• Primary sponsor: Sheba Medical Center
• Public title: Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS
• Scientific title: Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS
• Date of first enrolment: March 2005
• Target sample size: 50
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00444132
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
• Phase: Phase 3

Countries of recruitment

Israel

Contacts

• Name: Shlomi Matetzky, MD
• Affiliation: Senior Physician, ICCU, Sheba Medical Center.

Key inclusion & exclusion criteria

Inclusion Criteria:

- age equal or over 18 years

- acute coronary syndrome

- Clopidogrel non-responsive

- signed an informed consent

Exclusion Criteria:

- Bleeding disorder

- hypersensitivity to aspirin or clopidogrel

- any contraindication to anti-thrombotic or anticoagulant therapy

- active neoplastic disorder



Age minimum: 18 Years
Age maximum: 80 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Clopidogrel Non-Responsiveness

Intervention(s)

Drug: clopidogrel

Primary Outcome(s)

Platelet reactivity

Secondary Outcome(s)

death

stroke

recurrent ACS

Secondary ID(s)

SHEBA-05-3621-SM-CTIL

Source(s) of Monetary Support

Please refer to primary and secondary sponsors